These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2686726)

  • 1. Tumor markers in human biopsy material.
    Lehto VP; Pontén J
    Acta Oncol; 1989; 28(5):743-62. PubMed ID: 2686726
    [No Abstract]   [Full Text] [Related]  

  • 2. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
    Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
    Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report.
    Yu L; Li J; Xu S; Navia Miranda M; Wang G; Duan Y
    Diagn Pathol; 2016 Oct; 11(1):98. PubMed ID: 27733182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ITK/SYK translocation in angioimmunoblastic T-cell lymphoma.
    Attygalle AD; Feldman AL; Dogan A
    Am J Surg Pathol; 2013 Sep; 37(9):1456-7. PubMed ID: 24076779
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical Application of Cancer Molecular Diagnostics with Liquid Biopsy].
    Kubota M
    Rinsho Byori; 2016 Oct; 64(10):1156-1162. PubMed ID: 30609474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genes in the diagnosis of malignant disease. IFCC Scientific Division Committee on Molecular Biology Techniques.
    Wagener C
    J Int Fed Clin Chem; 1992 Dec; 4(5):222-7. PubMed ID: 10146702
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor markers in cancer diagnosis and prognosis.
    Virji MA; Mercer DW; Herberman RB
    CA Cancer J Clin; 1988; 38(2):104-26. PubMed ID: 3127000
    [No Abstract]   [Full Text] [Related]  

  • 8. Sclerosing TFEB-rearrangement renal cell carcinoma: a recurring histologic pattern.
    Williamson SR; Eble JN; Palanisamy N
    Hum Pathol; 2017 Apr; 62():175-179. PubMed ID: 27864122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor markers in infancy and childhood.
    Ricafort R
    Pediatr Rev; 2011 Jul; 32(7):306-8. PubMed ID: 21724907
    [No Abstract]   [Full Text] [Related]  

  • 10. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
    Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
    Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of circulating biomarkers in liquid biopsy diagnostics.
    Yeo JC; Lim CT
    Biotechniques; 2018 Oct; 65(4):187-189. PubMed ID: 30284936
    [No Abstract]   [Full Text] [Related]  

  • 13. Promises and limitations of biomarkers.
    Ransohoff DF
    Recent Results Cancer Res; 2009; 181():55-9. PubMed ID: 19213557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ETV6 Gene Rearrangements Characterize a Morphologically Distinct Subset of Sinonasal Low-grade Non-intestinal-type Adenocarcinoma: A Novel Translocation-associated Carcinoma Restricted to the Sinonasal Tract.
    Andreasen S; Skálová A; Agaimy A; Bishop JA; Laco J; Leivo I; Franchi A; Larsen SR; Erentaite D; Ulhøi BP; von Buchwald C; Melchior LC; Michal M; Kiss K
    Am J Surg Pathol; 2017 Nov; 41(11):1552-1560. PubMed ID: 28719468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
    Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
    Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGFBR3 and MGEA5 rearrangements in pleomorphic hyalinizing angiectatic tumors and the spectrum of related neoplasms.
    Carter JM; Sukov WR; Montgomery E; Goldblum JR; Billings SD; Fritchie KJ; Folpe AL
    Am J Surg Pathol; 2014 Sep; 38(9):1182-992. PubMed ID: 24705316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOX11 expression as a MRD molecular marker for MCL in comparison with t(11;14) and IGH rearrangement.
    Szostakowska M; Szymczyk M; Badowska K; Tudek B; Fabisiewicz A
    Med Oncol; 2018 Mar; 35(4):49. PubMed ID: 29520657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum tumor markers: diagnostic or para-diagnostic.
    Mehdi I
    J Pak Med Assoc; 1998 May; 48(5):118-20. PubMed ID: 9813969
    [No Abstract]   [Full Text] [Related]  

  • 19. Proliferation markers in tumours: interpretation and clinical value.
    van Diest PJ; Brugal G; Baak JP
    J Clin Pathol; 1998 Oct; 51(10):716-24. PubMed ID: 10023332
    [No Abstract]   [Full Text] [Related]  

  • 20. Judging new markers by their ability to improve predictive accuracy.
    Kattan MW
    J Natl Cancer Inst; 2003 May; 95(9):634-5. PubMed ID: 12734304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.